La Jolla Price to Sales Trend

LJPC -- USA Stock  

Quarterly Earning Report: October 23, 2019  

This module enables investors to look at La Jolla various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 1.5 M, Cost of Revenue of 1.5 M or Interest Expense of 6.5 M, but also many exotic indicators such as PPandE Turnover of 9.1757, Accounts Payable Turnover of 1.4864 or Accrued Expenses Turnover of 1.104. This module is a perfect complement to use when analyzing La Jolla Valuation or Volatility. It can also complement various La Jolla Technical models. Please see also analysis of La Jolla Correlation with competitors.

La Jolla Price to Sales Marginal Breakdown

Showing smoothed Price to Sales Ratio of La Jolla Pharmaceutical Company with missing and latest data points interpolated. Price to Sales Ratio is figured by comparing La Jolla Pharmaceutical stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on La Jolla sales, a figure that is much harder to manipulate than other La Jolla Pharmaceutical Company multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. An alternative calculation method to [PS]; that measures the ratio between a company's [Price] and it's Sales per Share.


          10 Years Trend
 Price to Sales Ratio 

La Jolla Regression Statistics

Arithmetic Mean 113.82
Geometric Mean 46.19
Coefficient Of Variation 144.72
Mean Deviation 136.32
Median 23.84
Standard Deviation 164.72
Sample Variance 27,133
Range 384.08
R Value 0.57
Mean Square Error 20,154
R Squared 0.32
Significance 0.05
Slope 26.03
Total Sum of Squares 298,466

La Jolla Price to Sales Over Time

2016  399.79 
2018  359.81 
2019  15.71 

Other Fundumenentals of La Jolla Pharmaceutical